Drug Trial Radar · NCT06717100
Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 17, 2024
Primary completion
Feb 17, 2025
Study completion Mar 17, 2025
Sponsor
- Lead sponsor
- PureTechIndustry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a trial of up to 60-day duration for safety, tolerability, and pharmacokinetics in healthy volunteers administered deupirfenidone (LYT-100) alone or in combination with nintedanib .
Conditions
- Drug Interactions
Interventions
Nintedanib 150 MG [Ofev]Drug
Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC of LYT-100 and NintedanibTime frame: Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100
- Tmax of LYT-100 and NintedanibTime frame: Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100
- Cmax of LYT-100 and NintedanibTime frame: Blood samples for PK analysis were collected on Days 7, 13, 20, and 30 to assess the steady-state plasma PK profiles of nintedanib and/or LYT-100
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty Ltd (Commercial Rd and St Kilda Rd) - VIC
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.